To print this article, all you need is to be registered or login on Mondaq.com.
The Dennemeyer Group has just released the findings from our
latest IP Trend Monitor study, which we conduct each year, together
with CTC Legal Media, to identify the most notable trends in
Intellectual Property (IP) management. For 2021 s edition, we
focused on the sector s work environment and its dramatic
transformation in response to the COVID-19 pandemic.
Given the speed with which the new SARS-CoV-2 coronavirus made
its way around the world, taking an immense toll on human life and
the global economy, many sectors had no choice but to transform the
/PRNewswire/ MGI, a subsidiary of BGI Group, announces today an official statement in response to the ruling of the Patents Court within the High Court of.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Illumina Wins Patent Infringement Suit against BGI in the UK
January 20, 2021 GMT
SAN DIEGO (BUSINESS WIRE) Jan 20, 2021
Illumina, Inc. (NASDAQ: ILMN) today announced that the High Court of Justice, Chancery Division, Patents Court, issued a judgment in its favor in the patent infringement suit filed against the BGI Companies, MGI Tech Co. Ltd; Latvia MGI SIA; MGI International Sales Co., Ltd; and BGI Complete Genomics Hong Kong Co., Ltd.
The Court found that four of the five asserted patents were valid and infringed by BGI. The Court ruled that BGI’s StandardMPS and CoolMPS systems infringe EP 1 530 537 B1, EP 3 002 289 B1, and EP 3 587 433 B1, and that StandardMPS also infringes EP 2 021 415 B1. These patents cover different aspects of Illumina’s proprietary sequencing-by-synthesis chemistry, including its azidomethyl reversible terminator and labelled nucleotides.
Illumina, Inc.: Illumina Wins Patent Infringement Suit against BGI in the UK
Illumina, Inc. (NASDAQ: ILMN) today announced that the High Court of Justice, Chancery Division, Patents Court, issued a judgment in its favor in the patent infringement suit filed against the BGI Companies, MGI Tech Co. Ltd; Latvia MGI SIA; MGI International Sales Co., Ltd; and BGI Complete Genomics Hong Kong Co., Ltd.
The Court found that four of the five asserted patents were valid and infringed by BGI. The Court ruled that BGI s StandardMPS and CoolMPS systems infringe EP 1 530 537 B1, EP 3 002 289 B1, and EP 3 587 433 B1, and that StandardMPS also infringes EP 2 021 415 B1. These patents cover different aspects of Illumina s proprietary sequencing-by-synthesis chemistry, including its azidomethyl reversible terminator and labelled nucleotides.